Skip to main content

A phase 3 randomized, double-blinded, placebo controlled multicenter trial with open label extesion to evaluate the efficacy, safety and tolerability of efgartigimod PH20

Open
  • Protocol code: ARGX-113-2306
  • EudraCT code: No aplica
  • Research group: Rheumatology
  • Service: Rheumatology
  • Principal investigator:  Marsal Barril, Sara
  • Pathology: Tumors
  • Phase: Fase III